Skip to main content
MedPathMedPath Home
Clinical Trials/NCT07450313
NCT07450313
Not yet recruiting
Phase 2

A Clinical Study on the Efficacy and Safety of Luspatercept in Improving Early Anemia After Allogeneic Hematopoietic Stem Cell Transplantation

Institute of Hematology & Blood Diseases Hospital, China0 sites20 target enrollmentStarted: March 14, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
InterventionsLuspatercept

Overview

Phase
Phase 2
Status
Not yet recruiting
Enrollment
20
Primary Endpoint
Cumulative volume of red blood cell transfusions
OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

This study aims to evaluate whether luspatercept can improve the efficacy and safety of anemia treatment in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation.

Detailed Description

This study aims to investigate whether the early post-transplant application of luspatercept can improve early anemia and transfusion dependency in patients with hematologic malignancies after hematopoietic stem cell transplantation. Meanwhile, the investigators aim to evaluate the safty of administration of luspatercept post-transplantation, and assess its impact on platelet and neutrophil engraftment, as well as its effect on the incidence of complications such as poor graft function.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •1\. Diagnosis of malignant hematological tumors and undergoing allogeneic hematopoietic stem cell transplantation.
  • •2\. Expected survival after transplantation exceeds 1 month.
  • •3\. Age 18-60 years.
  • •4\. Hemoglobin ≤60 g/L on day 0 after transplantation.
  • •5\. Eastern Cooperative Oncology Group (ECOG) score 0-
  • •6\. Able to independently sign the informed consent form.
  • •7\. The informed consent form must be signed before the start of the study procedures. For individuals aged 18 years and above, the informed consent form should be signed by the patient themselves or their immediate family members. Considering the patient's condition, if signing by the patient themselves is not conducive to treatment, the legal guardian or immediate family member should sign the informed consent form.

Exclusion Criteria

  • •1\. Uncontrolled infection at the time of enrollment, or requiring mechanical ventilation or hemodynamic instability;
  • •2\. Severe organic damage: hepatic or renal impairment;
  • •3\. Occurrence of any of the following within 6 months prior to the study: myocardial infarction, severe/unstable angina pectoris, congestive heart failure, or cerebrovascular accident, including transient ischemic attack;
  • •4\. Presence of psychiatric disorders or other conditions that may compromise compliance with study treatment and monitoring requirements. Failure to sign the informed consent form;
  • •5\. Inability or unwillingness to sign the consent form;
  • •6\. Participation in other transplant-related clinical studies;
  • •7\. Other circumstances deemed by the investigator as potentially affecting the study or ethics, including drug allergies, patient non-compliance with study procedures, or involvement of the research center staff and their immediate relatives.

Arms & Interventions

Luspatercept treatment

Experimental

Intervention: Luspatercept (Drug)

Outcomes

Primary Outcomes

Cumulative volume of red blood cell transfusions

Time Frame: 28 days post-HSCT

Secondary Outcomes

  • Cumulative volume of red blood cell transfusions(56 days post-transplantation)
  • Platelet and neutrophil counts(2 months post-HSCT)
  • Incidence of poor graft function (PGF).(one year post-HSCT)
  • Serum/bone marrow GATA1,and GDF11 levels(2 months post-HSCT)
  • Levels of inflammatory factors(2 months post-HSCT)
  • Incidence of acute graft-versus-host disease (aGVHD).(one year post-HSCT)
  • Overall Survival(one year after HSCT)
  • disease-free survival(one year after HSCT)
  • cumulative incidence of relapse(one year after HSCT)
  • treatment-related mortality(one year after HSCT)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials

Not yet recruiting
Phase 2
LUSPARA - Luspatercept in patients affected with rare inherited anemias
2024-520200-26-00Eurobloodnet Association45
Recruiting
Phase 2
Phase 2 Study of Luspatercept in Adults and Adolescents with Alpha (α)-thalassemia
2022-502328-35-00Celgene Corp.41
Not yet recruiting
Phase 2
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant to Prior Treatments, Who Require Red Blood Cell Transfusion.
2024-519310-31-00Associazione Qol-One22
Active, not recruiting
Phase 2
Evaluation of the efficacy and safety of empagliflozin in the treatment of neutropenia in patients with glycogenosis Ib. EMPAtia.
2024-512840-52-00Instytut Pomnik Centrum Zdrowia Dziecka20
Recruiting
Phase 2
Phase 2a Study of Luspatercept in Pediatric Participants With Beta (β)-Thalassemia
2022-502499-22-00Celgene Corp.57